IPO
ADOCIA announces its financial results, including revenue and cash position, for the quarter ended March 31st, 2019.
Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.
NOXXON Pharma N.V. announced its financial results for the fiscal year ending December 31, 2018.
Polyphor AG shareholders approved all motions put forward by the Board of Directors to the 22nd Annual General Meeting in Basel.
The shareholders in Recipharm AB (publ), reg. no. 556498-8425, are hereby invited to attend the Annual General Meeting (“AGM”) to be held on Monday 13 May 2019 at 3.00 pm at IVA Konferenscenter, Grev Turegatan 16 in Stockholm, Sweden.
The new accounting standard, IFRS 16 will have an estimated positive impact on EBITDA of SEK 90 million in 2019.
Heidelberg Pharma AG reported on the first three months of fiscal year 2019 (1 December 2018 - 28 February 2019) and the Group’s financial figures.
Pharming Group N.V. announces that the Notice to Convene for its Annual General Meeting of Shareholders has been uploaded on its website.
The shareholders in BioArctic AB, corporate identity number 556601-2679 are hereby summoned to the Annual General Meeting to be held on May 9, 2019, at 5 p.m., at Grant Thornton Sweden AB’s offices, Sveavägen 20, Stockholm, Sweden.
MorphoSys AG announced that it has published its agenda for the Company’s ordinary Annual General Meeting, which will take place on Wednesday, May 22, 2019.
PRESS RELEASES